178 related articles for article (PubMed ID: 1682794)
1. Antineoplastic drug resistance in brain tumors.
Phillips PC
Neurol Clin; 1991 May; 9(2):383-404. PubMed ID: 1682794
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
Poste G
Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
6. Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.
Beck WT
Bull Cancer; 1990; 77(11):1131-41. PubMed ID: 1980425
[TBL] [Abstract][Full Text] [Related]
7. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
8. [Perspectives on modulation of chemoresistance of malignant diseases].
Allerödder HP; Ukena D; Sybrecht GW
Pneumologie; 1993 Sep; 47(9):513-7. PubMed ID: 7901849
[No Abstract] [Full Text] [Related]
9. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
11. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
12. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
13. Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.
Joo KM; Song SY; Park K; Kim MH; Jin J; Kang BG; Jang MJ; Lee GS; Kim MS; Nam DH
Int J Oncol; 2008 Oct; 33(4):705-12. PubMed ID: 18813783
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic analysis of in vitro and in vivo brain tumor models.
Schuster JM; Friedman HS; Bigner DD
Neurol Clin; 1991 May; 9(2):375-82. PubMed ID: 1944106
[TBL] [Abstract][Full Text] [Related]
15. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Redmond SM; Joncourt F; Buser K; Ziemiecki A; Altermatt HJ; Fey M; Margison G; Cerny T
Cancer Res; 1991 Apr; 51(8):2092-7. PubMed ID: 1672623
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
Osmak M
Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell drug resistance and its reversal.
Mansouri A; Henle KJ; Nagle WA; Moss AJ
SAAS Bull Biochem Biotechnol; 1990 Jan; 3():91-6. PubMed ID: 1366508
[TBL] [Abstract][Full Text] [Related]
18. Resistance mechanisms in murine tumors with acquired multidrug resistance.
Volm M; Efferth T; Mattern J; Pommerenke EW
Arzneimittelforschung; 1992 Sep; 42(9):1163-8. PubMed ID: 1445488
[TBL] [Abstract][Full Text] [Related]
19. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
20. [Multidrug resistance of neoplastic cells--facts and hypotheses].
Grzelakowska-Sztabert B
Postepy Biochem; 1989; 35(4):513-41. PubMed ID: 2577370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
